Autres langues Sprint Bioscience AB

Actions

SPRINT

SE0006343745

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
3,150 ^SEK	0,00%		-4,83%	+114,29%

23/07	Sprint Bioscience AB et Eli Lilly and Company concluent un accord pour accélérer le développement de médicaments	CI
26/06	Quatre actions atteignent un nouveau sommet annuel sur la Bourse de Stockholm	FW

Autres langues

13/08	Sprint Bioscience's Upcoming Conferences and Investor Events
23/07	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development
23/07	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development
04/06	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company
19/05	Sprint Bioscience (Q1 Review): Momentum in the business
13/05	Sprint Bioscience Q1 operating loss SEK 14.3 mln
13/05	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026
16/04	Sprint Bioscience completes strategic evaluation of STK25 program
16/04	Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication
16/04	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation
01/04	Sweden's Sprint Bioscience Names New CFO
01/04	Sprint Bioscience appoints Jenni Björnulfson as CFO
01/04	Sprint Bioscience appoints Jenni Björnulfson as CFO
01/04	Sprint Bioscience reports positive proof-of-concept results from program in CKD
01/04	Positive results expand the NNMT program into Chronic Kidney Disease
01/04	Sprint Bioscience AB Expands NNMT Program into Chronic Kidney Disease
01/04	Sprint Bioscience AB Appoints Jenni Björnulfson as Chief Financial Officer, Effective May 4, 2026
01/04	Sprint Bioscience AB Appoints Jenni Björnulfson to Management Team, Effective May 4, 2026
27/03	Sprint Bioscience publishes new research findings that strengthen the potential of DCPS inhibitors in AML
27/03	Sprint Bioscience AB Publishes New Research Findings That Strengthen the Potential of Dcps Inhibitors in Aml
18/03	Sprint Bioscience AB Presents New Preclinical Data On Dcps Program At The Aacr Annual Meeting
18/03	Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026
17/03	Sprint Bioscience reports positive results from the VRK1 program
17/03	Sprint Bioscience reports positive results from the VRK1 program
17/03	Sprint Bioscience AB Announces Positive Results From The VRK1 Program